These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32407269)

  • 1. Pharmacogenetic Evaluation of Metformin and Sulphonylurea Response in Mexican Mestizos with Type 2 Diabetes.
    Marta M; Sánchez-Pozos K; Jaimes-Santoyo J; Monroy-Escutia J; Rivera-Santiago C; de Los Ángeles Granados-Silvestre M; Ortiz-López MG
    Curr Drug Metab; 2020; 21(4):291-300. PubMed ID: 32407269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.
    Dujic T; Zhou K; Yee SW; van Leeuwen N; de Keyser CE; Javorský M; Goswami S; Zaharenko L; Hougaard Christensen MM; Out M; Tavendale R; Kubo M; Hedderson MM; van der Heijden AA; Klimčáková L; Pirags V; Kooy A; Brøsen K; Klovins J; Semiz S; Tkáč I; Stricker BH; Palmer C; 't Hart LM; Giacomini KM; Pearson ER
    Clin Pharmacol Ther; 2017 Jun; 101(6):763-772. PubMed ID: 27859023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population diversity of three variants of the SLC47A2 gene (MATE2-K transporter) in Mexican Mestizos and Native Americans.
    Favela-Mendoza AF; Fricke-Galindo I; Cuevas-Sánchez WF; Aguilar-Velázquez JA; Martínez-Cortés G; Rangel-Villalobos H
    Mol Biol Rep; 2021 Sep; 48(9):6343-6348. PubMed ID: 34383246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
    Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
    J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal assessment of SNPs rs72552763 and rs622342 in
    Ortega-Ayala A; De Andrés F; Llerena A; Bartolo-Montiel CM; Acosta-Altamirano G; Molina-Guarneros JA
    Front Pharmacol; 2024; 15():1433519. PubMed ID: 39403148
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of
    Ortega-Ayala A; De Andrés F; Llerena A; Bartolo-Montiel CM; Molina-Guarneros JA
    Biomed Rep; 2024 Aug; 21(2):117. PubMed ID: 38938740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients.
    Raj GM; Mathaiyan J; Wyawahare M; Priyadarshini R
    Drug Metab Pers Ther; 2018 Dec; 33(4):175-185. PubMed ID: 30433870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review.
    Mofo Mato EP; Guewo-Fokeng M; Essop MF; Owira PMO
    Medicine (Baltimore); 2018 Jul; 97(27):e11349. PubMed ID: 29979413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Influence of OCT3 and MATE2 Genetic Polymorphisms in Poor Response to Metformin in Type 2 Diabetes Mellitus.
    Naem AAA; Al-Terehi MN; Ghafil FA; Ataya FS; Batiha GE; Alexiou A; Papadakis M; Welson NN; Hadi NR
    Endocrinol Diabetes Metab; 2024 Sep; 7(5):e486. PubMed ID: 39086121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Pharmacogenet Genomics; 2010 Jan; 20(1):38-44. PubMed ID: 19898263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer.
    Berstein LM; Iyevleva AG; Vasilyev D; Poroshina TE; Imyanitov EN
    Cell Cycle; 2013 Dec; 12(23):3681-8. PubMed ID: 24145224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
    Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
    Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai.
    Zhou Y; Ye W; Wang Y; Jiang Z; Meng X; Xiao Q; Zhao Q; Yan J
    Int J Clin Exp Pathol; 2015; 8(8):9533-42. PubMed ID: 26464716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.
    Pérez-Gómez N; Fernández-Ortega MD; Elizari-Roncal M; Santos-Mazo E; la Maza-Pereg L; Calvo S; Alcaraz R; Sanz-Solas A; Vinuesa R; Saiz-Rodríguez M
    Pharmacogenomics; 2023 Aug; 24(12):651-663. PubMed ID: 37610884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis.
    Peng A; Gong C; Xu Y; Liang X; Chen X; Hong W; Yan J
    Front Public Health; 2023; 11():1183879. PubMed ID: 37546319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes.
    Phani NM; Vohra M; Kakar A; Adhikari P; Nagri SK; D'Souza SC; Umakanth S; Satyamoorthy K; Rai PS
    Pharmacogenomics; 2018 Jul; 19(11):905-911. PubMed ID: 29914345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C9*3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide.
    Castelán-Martínez OD; Hoyo-Vadillo C; Bazán-Soto TB; Cruz M; Tesoro-Cruz E; Valladares-Salgado A
    J Clin Pharm Ther; 2018 Dec; 43(6):768-774. PubMed ID: 29802808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients.
    Umamaheswaran G; Praveen RG; Damodaran SE; Das AK; Adithan C
    Clin Exp Med; 2015 Nov; 15(4):511-7. PubMed ID: 25492374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes.
    Tkáč I; Klimčáková L; Javorský M; Fabianová M; Schroner Z; Hermanová H; Babjaková E; Tkáčová R
    Diabetes Obes Metab; 2013 Feb; 15(2):189-91. PubMed ID: 22882994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of Metformin Transporters Suggests No Association with Therapeutic Inefficacy among Diabetes Type 2 Mexican Patients.
    Ortega-Ayala A; Rodríguez-Rivera NS; Andrés F; LLerena A; Pérez-Silva E; Espinosa-Sánchez AG; Molina-Guarneros JA
    Pharmaceuticals (Basel); 2022 Jun; 15(7):. PubMed ID: 35890074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.